Omeros Corporation (NASDAQ:OMER – Get Free Report)’s stock price gapped down before the market opened on Tuesday. The stock had previously closed at $16.68, but opened at $14.59. Omeros shares last traded at $13.62, with a volume of 778,506 shares trading hands.
Key Omeros News
These are some of the OMER news items that stood out recently:
- Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $33 price target, signaling substantial upside in the analyst’s view. HC Wainwright rating
- Neutral Sentiment: Omeros expects $5 million to $6 million of fourth-quarter income from discontinued operations, while continuing efforts to scale YARTEMLEA use. Q4 outlook
- Negative Sentiment: Third-quarter revenue was $35.9 million, below analysts’ roughly $37.3 million estimate. Although non-GAAP EPS of $0.06 topped forecasts, reports highlighted a wider quarterly loss, weighing on sentiment. Omeros shares down on wider third-quarter loss
Analyst Upgrades and Downgrades
Several research firms have recently commented on OMER. HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of Omeros in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and set a $22.00 price target on shares of Omeros in a research report on Wednesday, October 14th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $30.33.
View Our Latest Research Report on OMER
Omeros Stock Down 19.0%
The firm has a market capitalization of $977.63 million, a PE ratio of 10.56 and a beta of 2.96. The business’s fifty day moving average price is $18.22 and its 200 day moving average price is $13.76.
Omeros (NASDAQ:OMER – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.04. The firm had revenue of $35.93 million for the quarter, compared to analysts’ expectations of $37.28 million. As a group, sell-side analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, Director Thomas J. Cable sold 15,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the sale, the director owned 35,067 shares in the company, valued at $646,986.15. This trade represents a 29.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO David J. Borges sold 10,000 shares of Omeros stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total value of $209,500.00. Following the completion of the sale, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at approximately $104,750. This represents a 66.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 100,906 shares of company stock valued at $1,904,955. Insiders own 10.50% of the company’s stock.
Institutional Trading of Omeros
A number of hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its holdings in Omeros by 3.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,708 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 589 shares during the period. Sterling Capital Management LLC lifted its holdings in shares of Omeros by 75.3% during the 3rd quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 758 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of Omeros by 13.6% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,500 shares of the biopharmaceutical company’s stock worth $333,000 after acquiring an additional 2,100 shares during the last quarter. Brighton Jones LLC grew its holdings in Omeros by 9.9% in the third quarter. Brighton Jones LLC now owns 34,739 shares of the biopharmaceutical company’s stock valued at $661,000 after purchasing an additional 3,142 shares during the period. Finally, GK Wealth Management LLC purchased a new position in Omeros during the third quarter worth approximately $65,000. 48.79% of the stock is owned by institutional investors and hedge funds.
Omeros Company Profile
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
Read More
- Five stocks we like better than Omeros
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
